

RESEARCH

Open Access

Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment

Mari Hirvinen^{1,2}, Raita Heiskanen³, Minna Oksanen¹, Saira Pesonen¹, Ilkka Liikanen¹, Timo Joensuu⁴, Anna Kanerva^{1,5}, Vincenzo Cerullo^{2*†} and Akseli Hemminki^{1,3,4*†}

Abstract

Background: Oncolytic viruses have shown potential as cancer therapeutics, but not all patients seem to benefit from therapy. Polymorphisms in Fc gamma receptors (FcγRs) lead to altered binding affinity of IgG between the receptor allotypes and therefore contribute to differences in immune defense mechanisms. Associations have been identified between FcγR polymorphisms and responsiveness to different immunotherapies. Taken together with the increasing understanding that immunological factors might determine the efficacy of oncolytic virotherapy we studied whether FcγR polymorphisms would have prognostic and/or predictive significance in the context of oncolytic adenovirus treatments.

Methods: 235 patients with advanced solid tumors were genotyped for two FcγR polymorphisms, FcγRIIIa-H131R (rs1801274) and FcγRIIIa-V158F (rs396991), using TaqMan based qPCR. The genotypes were correlated with patient survival and tumor imaging data.

Results: In patients treated with oncolytic adenoviruses, overall survival was significantly shorter if the patient had an FcγRIIIa-VV/ FcγRIIIa-HR (VVHR) genotype combination ($P = 0,032$). In contrast, patients with FFHR and FFRR genotypes had significantly longer overall survival ($P = 0,004$ and $P = 0,006$, respectively) if they were treated with GM-CSF-armed adenovirus in comparison to other viruses. Treatment of these patients with unarmed virus correlated with shorter survival ($P < 0,0005$ and $P = 0,016$, respectively). Treating FFHH individuals with CD40L-armed virus resulted in longer survival than treatment with other viruses ($P = 0,047$).

Conclusions: Our data are compatible with the hypothesis that individual differences in effector cell functions, such as NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) and tumor antigen presentation by APCs caused by polymorphisms in FcγRs could play role in the effectiveness of oncolytic virotherapies. If confirmed in larger populations, FcγR polymorphisms could have potential as prognostic and predictive biomarkers for oncolytic adenovirus therapies to enable better selection of patients for clinical trials. Also, putative associations between genotypes, different viruses and survival implicate potentially important mechanistic issues.

Keywords: Fc gamma receptor (FcγR), Oncolytic virus, NK cell, GM-CSF, CD40L

* Correspondence: vincenzo.cerullo@helsinki.fi; akseli.hemminki@helsinki.fi

†Equal contributors

²Laboratory of Immunovirotherapy, Division of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, Helsinki 00790, Finland

¹Cancer Gene Therapy Group, Department of Pathology and Transplantation laboratory, Haartman Institute, University of Helsinki, Haartmaninkatu 3, Helsinki 00290, Finland

Full list of author information is available at the end of the article

Background

Oncolytic viruses are modified to selectively kill cancer cells by replicating in them. Replicating viruses have shown promising efficacy in human clinical trials as cancer therapeutics but the treatment is usually not curative, especially in the context of advanced cancer [1]. Immunological factors are currently believed to play a crucial role in determining the efficacy of the treatment or the lack thereof [2,3]. Adenoviruses per se are known to be highly immunogenic but it seems that even stronger stimulation of patient's own immune system is required to fully overcome the immunosuppressive tumor microenvironment and to ensure a long-lasting effect. In this regard, boosting the immunogenicity of the virus e.g. by inserting immunostimulatory transgenes has shown intriguing results [4,5]. However, patients receiving oncolytic virotherapy seem to respond differently to the treatments, some benefiting more than the others. Individual differences in the efficiency of the patients' immune system and antigen recognition might play a crucial role in determining the response to viral treatment. However, currently there are no biomarkers available for selecting the right patients for such therapy or vice versa.

Fc gamma receptors (FcγRs) have been recognized as key players in immune defense mechanisms against foreign cells and pathogens. In previous studies, single nucleotide polymorphisms in FcγRIIa and FcγRIIIa genes have not only been associated with susceptibility to various diseases such as autoimmune disorders [6,7], infectious diseases [8] and coagulation defects [9], but also with disease progression and responsiveness to immunological therapies, such as mAb therapies [10,11] and cancer vaccinations [12,13]. For example, Musolino et al. showed association between FcγRIIa and FcγRIIIa polymorphisms and clinical outcome of trastuzumab treated breast cancer patients [11], where individuals with VV and HH genotypes had better survival and response rates compared to patients with other genotypes. Similar results were seen in rituximab treated B-cell lymphoma patients [14,15]. Cetuximab therapy for colorectal cancer was also seen to be more effective for individuals with HH genotype [16,17], although there has been conflicting data published for the allele giving the best outcome [16,18,19].

Polymorphisms in FcγRIIa and FcγRIIIa have also been shown relevant for cancer vaccines. A positive correlation was observed between the outcome of patients treated with idiotypic vaccination against B-cell lymphoma and the FcγRIIIa-VV genotype [20]. FcγRIIa-131R and FcγRIIIa-158 V allotypes were associated with significantly better overall in survival of colorectal carcinoma patients receiving either passively administered monoclonal antibodies or antibodies induced by carcinoembryonic antigen (CEA) vaccination [13]. Because oncolytic adenoviruses are known to elicit strong immune reactions in patients

[21], and it is increasingly understood that immunological factors determine the efficacy of the treatment or lack thereof [3], we wanted to assess if FcγR polymorphisms play a role.

FcγRs are glycoproteins that are part of the immunoglobulin superfamily expressed on leukocytes. These receptors have a major role in antigen recognition during immune response. They serve as a link between humoral and cell-mediated immune systems, but also between innate and adaptive immune responses [22]. FcγRs can be divided into three classes, FcγRI, FcγRII and FcγRIII, which differ in structure, cell distribution and also in affinity and specificity to different IgG subtypes. Each of these receptor classes can in turn be split into subclasses, indicated with letters (a, b or c). In contrast to FcγRI, which exhibits high affinity to monomeric IgG, FcγRII and FcγRIII are capable of binding effectively only aggregated, multimeric IgG that is bound to an antigen [23]. Binding of antigen-bound IgG leads to activation of FcγRs through phosphorylation of the ITAM/ITIM signaling unit by tyrosine kinases leading to activation of various downstream targets, eventually resulting in changes in effector cell functions. Effector cells bearing FcγRs can destroy target Ag-Ab complexes by multiple mechanisms. FcγRs can regulate effector cell functions including phagocytosis, degranulation, antibody-dependent cellular cytotoxicity (ADCC), cytokine and chemokine expression or antibody production by B-cells [23-25].

At least eleven polymorphic regions can be found in FcγR genes, and copy number variation has also been reported [26]. Among different subclasses, FcγRIIa and FcγRIIIa play the most important role in immune regulation and their polymorphisms have been most often associated with diseases and disease severity in previous studies.

FcγRIIa (CD32a) is one of the three possible receptor subclasses expressed from *FCGR2A* genes. It has low affinity to monomeric IgG, but binds effectively to aggregated IgG and Ag-Ab immune complexes. FcγRIIa is expressed on monocytes, macrophages, neutrophils, certain dendritic cells (DCs) and also on platelets, which is unique among all FcγRs [22]. FcγRIIa has a wide cellular distribution, but it is mainly expressed on phagocytic cells such as macrophages and neutrophils, and is commonly involved in the process of phagocytosis and clearance of immune complexes [27]. A single nucleotide polymorphism (SNP) in FcγRIIa, FcγRIIa-H131R (rs1801274), alters the binding affinity of the receptor to IgG between the two possible receptor allotypes. In this polymorphism, a missense mutation (guanine (G) -> adenine (A)) in *FCGR2A* gene results in amino acid change, histidine (H) to arginine (R), in amino acid position 131 in the receptor's extracellular ligand-binding domain. The FcγRIIa-R allotype binds weaker to IgG (especially to IgG2) than the ancestral H allotype. This variation leads to functional difference

between the two allotypes. Effector cells of homozygous individuals for FcγRIIIa-H are more effective in recognizing and clearing IgG2-coated antigens than cells of FcγRIIIa-R homozygous individuals. Heterozygous individuals (FcγRIIIa-HR) have effector cells bearing both allotypes of the receptor and are referred to as “intermediate immune responders” regarding FcγR functions. FcγRIIIa-R allotype binds also other IgG subtypes weaker than H allotype [23].

The polymorphism in FcγRIIIa, FcγRIIIa-V158F (rs396991), leads also to different binding affinity to IgG between the two different isoforms of the receptor. *FCGR3A* gene has a thymine (T) to guanine (G) missense mutation in amino acid position 158 which changes the valine (V) to phenylalanine (F) in the ligand-binding domain of the receptor. The FcγR-V158 allotype has a stronger binding affinity to IgG1, IgG3 and IgG4 than the F form [23]. It is noteworthy that binding of IgG4 is limited only to the V158 allotype of the receptor [22]. FcγRIIIa are found mostly on natural killer cells (NKs), but also on tissue-specific macrophages and on a subset of monocytes, γδ T-cells and DCs. NK-cells are major components of the cellular defense system against foreign or infected tissue and could be especially relevant in the context of granulocyte-macrophage colony-stimulating factor (GM-CSF) coding oncolytic viruses, since increased activity of NK cells through DC recruitment is one of the expected mechanisms of action of the transgene [28]. Tumor cells are known to have often lost their MHC class I protein expression, which is needed to activate cytotoxic T lymphocyte (CTL) –mediated cell killing. NK-cells do not need MHC I antigen presentation to be able to recognize and destroy an infected tumor cell since they express FcγRIIIa receptors that can bind antibodies bound to antigens presented on target cells. Triggering of NK-cell FcγRIIIa induces ADCC and lymphokine production underlining the central role of this receptor in host defense against viral infections and malignancies [23,29]. Also FcγRIIIa on macrophages (e.g. Kupffer cells in the liver) are thought to play a role in the clearance of circulating immune complexes [22,23].

The role of FcγR polymorphisms in determining the efficacy of immunotherapies is increasingly recognized. Here, we assessed the association of FcγRIIIa and FcγRIIIa with clinical response to, and survival post oncolytic adenovirus therapy.

Materials and methods

Patient samples

Analysis carried out in the present study are based on a series of 235 individuals (98 males and 137 females; age median 58 years) with advanced solid tumors refractory to available treatment modalities. These patients were treated with oncolytic adenoviruses in an Advanced

Therapy Access Program (ATAP). ATAP was regulated by Finnish Medicines Agency (FIMEA) as determined by EU EC/1394/2007. The inclusion and exclusion criteria have been reported elsewhere [30,31]. The analyses reported here have been approved by HUCH (Helsinki University Central Hospital) Operative Ethics committee.

71,9% of patients included in this present study have been treated with GM-CSF-armed viruses, 15,7% with CD40L-armed viruses and 7,2% with both GM-CSF and CD40L-armed viruses. Other relevant clinical data are shown in Table 1.

Peripheral blood samples were originally collected from patients to assess presence of virus (biosafety, efficacy and safety implications). Since receptor polymorphisms could also impact safety or efficacy, the same samples were used for FcγR SNP genotyping with Ethics committee permission.

DNA extraction

Genomic DNA was extracted from patient clot samples by using a QiAmp Blood Mini Kit (Qiagen, Germany). First the samples were thawed in a 37°C water bath and then the clots were transferred into clot spin basket

Table 1 Patient characteristics

No. of patients	235
<i>Age (years when treatments started)</i>	
Range	3-82
Medium	58
<i>Sex (No. (%))</i>	
Female	137 (58,3%)
Male	98 (41,7%)
<i>Cancer type (No. (%))</i>	
Colorectal, intestinal and anal	42 (17,9%)
Ovarian (also tubal)	35 (14,9%)
Breast	29 (12,3%)
Sarcomas	21 (8,9%)
Pancreatic and papilla vater	20 (8,5%)
Lung	18 (7,7%)
Neuroblastoma	14 (6,0%)
Prostate	12 (5,1%)
Skin and melanomas	11 (4,7%)
Liver and mesothelioma	9 (3,8%)
Gastric	6 (2,6%)
Biliary tract or cholangio	5 (2,1%)
Urinary tract or bladder	4 (1,7%)
Cervix and endometrial	3 (1,3%)
Renal	3 (1,3%)
Thyroid, thymus or parathyroid	2 (0,9%)
Esophageal	1 (0,4%)

filters (Qiagen, Germany). Samples were spun through the filter by centrifugation (2000 rcf, 5 min., RT). Qiagen QiAmp Blood Mini Kit DNA extraction protocol was used for the DNA extraction. DNA was eluted in nuclease free water (Amresco LLC, Solon, OH, USA) and stored in -20°C freezer until genotype analysis. DNA concentrations were measured by using NanoDrop ND-1000 (Thermo Fisher Scientific, Wilmington, DE, USA). For genotype analyses DNA samples were diluted in nuclease free water (Amresco) to get a final concentration of 1 ng/μl.

Genotyping

Patients were genotyped for two different Fc gamma receptor polymorphisms, FcγRIIa-H131R (rs1801274) and FcγRIIIa-V158F (rs396991) using TaqMan technology [32] on Applied Biosystems (AB) 7500 Fast Real-Time PCR system (Applied Biosystems Inc., CA, USA). Probes and primers (TaqMan SNP Assays for rs1801274 and rs396991) were ordered from Applied Biosystems. Genotyping was performed by manufacturer's instructions. Briefly, polymerase chain reactions were prepared in MicroAmp Fast Optical 96-well Reaction Plates (AB) in final volume of 25 μl. The reaction mixes consisted of 2× TaqMan Genotyping Master Mix (AB) and 20× TaqMan SNP Assay Mix (AB) for either FcγRIIa or FcγRIIIa polymorphism. 10 ng of genomic template DNA sample was added per well. Each sample was set up as triplicate. Nuclease free water (Amresco) was used as No Template Control (NTC). Following PCR program was used: initiation at 60°C for 2 minutes and AmpliTaq Gold Enzyme activation at 95°C for 10 minutes followed by 45 cycles of denaturation at 92°C for 15 seconds and annealing and extension at 60°C for 1 minute, allelic discrimination plate read was performed at 60°C for 1 minute. The FcγR genotypes were determined using Allelic Discrimination protocol in the Sequence Detection System (SDS) software provided by Applied Biosystems.

Statistical analysis

The Pearson's Chi-square (χ^2) test was used to assess Hardy-Weinberg equilibrium of genotype and allele frequencies by using OEGE (Online Encyclopedia for Genetic Epidemiology studies) Hardy-Weinberg equilibrium calculator [33]. CubeX (Cubic Exact Solution) software [34] and EM (expectation-maximisation) algorithms [35] were used for analyzing linkage disequilibrium between the two polymorphic loci. The χ^2 test was used to compare outcomes of the patients according to FcγR polymorphisms. Outcome data were divided to disease control (DC) (i.e. stable disease or better) or to progressive disease (PD) according to patients' imaging (RECIST or PET criteria [36]) and tumor marker data. Kaplan-Meier survival estimations [37] and log-rank statistics [38] were used to determine the differences in the overall survival (OS) and

median time to death. OS was calculated from the date of initiation of the adenovirus therapy to the date of death or to the date of last follow-up when data were censored. The statistical data were obtained by using IBM SPSS Statistics 20 software for Windows (SPSS Inc., Chicago, IL, USA). All *P* values are two-sided and considered statistically significant when $\leq 0,05$.

Results

Genotypic frequencies of polymorphisms


DNA from 235 patients with advanced cancers refractory to conventional therapies treated with oncolytic virotherapy were genotyped for FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms by TaqMan-based qPCR. Genotyping was successful for all patients. Frequencies of FcγRIIa and FcγRIIIa polymorphisms did not differ significantly from the expected ratios of Hardy-Weinberg equilibrium with $\chi^2 = 0,72$ ($P < 0,5$) and $\chi^2 = 0,01$ ($P < 0,9$), respectively. By using a 2-locus linkage disequilibrium analysis for these two polymorphic receptor loci, some linkage disequilibrium (LD), i.e. non-random distribution of alleles, was observed ($D' = 0,28$; $P < 0,01$). The observed frequencies and results of LD analysis are shown in Additional file 1: Table S1.

Analyses of patient survival and treatment responses according to FcγRIIa and FcγRIIIa genotypes

The median overall survival (OS) time after the first treatment with oncolytic adenoviruses of the studied patients was 130 days. We performed survival estimations for the different genotypes of both FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms by using the Kaplan-Meier analysis to assess whether some of the genotypes would be prognostic of prolonged survival of patients treated with oncolytic adenoviruses. We did not observe any statistically significant differences in OS based on FcγRIIa/IIIa genotypes (FcγRIIa HH vs. HR vs. RR, $P = 0,335$; FcγRIIIa VV vs. VF vs. FF, $P = 0,193$) (Figure 1). In addition, no significant difference in the distribution of clinical responses (disease control (DC) or progressive disease (PD)) was observed between patients with either FcγRIIa HH, HR or RR genotype (42,1%/57,9% vs. 43,7%/56,3% vs. 37,5%/62,5%; $P = 0,842$). Similarly, no statistically significant difference in the clinical responses was observed between patients with either FcγRIIIa VV, VF or FF genotype (45,5%/54,5% vs. 37,9%/62,1% vs. 44,6%/55,4%; $P = 0,730$) (Additional file 1: Figure S1). Thus, there was no difference in survival or disease control in association with any of the genotypes individually.

Analyses of patient survival according to combinations of FcγRIIa and FcγRIIIa genotypes

Because it is known that FcγRs have different expression patterns and biologic significance in different cell types,



all of which could contribute to the overall immunological response, we analyzed the combinations of FcgR genotypes (see Additional file 1: Table S2 for observed genotype combinations). We assessed the survival estimations for the different genotype combinations of FcgRIIa-H131R and FcgRIIIa-V158F polymorphisms by using the Kaplan-Meier analysis (Figure 2). Interestingly, one genotype combination, FcgRIIIa-VV and FcgRIIa-HR (VVHR), stood out as a prognostic factor for poor survival after oncolytic adenovirus treatments ($P = 0,032$). Additionally, FcgRIIIa-VF and FcgRIIa-HH (VFHH) genotype combination displayed a borderline trend towards good overall survival, although the correlation was not significant ($P = 0,079$).


The VVHR genotype combination is prognostic and predictive of long survival in patients treated with oncolytic adenoviruses

In the Kaplan-Meier survival analyses we observed that patients with a VVHR genotype combination had an overall survival (time from the first virus treatment) estimate significantly shorter than patients with any other genotype combinations with a median of 113 (95% CI: 54,1-171,9) versus 138 (95% CI: 112,6-163,4) days, respectively (Figure 3a). When the survival after cancer diagnosis was compared between patients with VVHR genotype combination and all others, no significant difference could be observed ($P = 0,248$), supporting the notion that the genotype is not prognostic for cancer patients *per se*, but

only in the context of oncolytic virotherapy (Figure 3b). Thus, in fact this genotype is not a pure prognostic factor but also predictive of poor survival in patients treated with oncolytic adenovirus. Although the trend was clear, and in accord with the survival result, no statistically significant difference in disease control versus progressive disease was observed between patients with either VVHR or other genotype combinations (20,0%/80,0% vs. 42,6%/57,4%; $P = 0,314$) probably due to the limited amount of patients bearing VVHR genotype with an evaluable objective outcome (Figure 3c).

Different arming molecules have different impacts on survival of patients with different FcgR genotypes

GM-CSF and CD40L are both potent recruiters and activators of immune cells and they are also essential for FcgR-mediated effector cell functions. Thus, we studied if the arming molecule present in the virus has also an impact on the survival of patients with different FcgR genotypes (Additional file 1: Table S3) and genotype combinations (Table 2). Overall, patients treated with armed viruses lived longer regardless of genotype. Interestingly, patients with FFHR and FFRR genotypes had significantly longer overall survival after first virus treatment if they were treated with GM-CSF-armed adenovirus, in comparison to other viruses ($P = 0,004$ and $P = 0,006$ respectively) (Figures 4a and 4b). In contrast, treatment of these patients with unarmed virus correlated with shorter survival ($P < 0,0005$ and $P = 0,016$, respectively).




Treating FFHH individuals with CD40L-armed virus resulted in longer survival than treatment with other viruses ($P = 0,047$) (Figure 4c).

Discussion

Oncolytic virotherapy has been proposed a potent approach for treatment of advanced cancers. However, it is becoming increasingly recognized that there is variance

in efficacy between treated patients; Some patients seem to respond better to the therapy than others. A similar phenomenon has also been observed with some other immunotherapeutics, including monoclonal antibodies [17] and cancer vaccines [12,13]. As immunological aspects have been reported important for the efficacy of oncolytic viruses [5,21,39,40], we hypothesized that there may be some germline differences in the immunological



mechanisms of patients that might in part explain differences in response to oncolytic virotherapy. One of these could be Fc gamma receptors (FcγRs), which are known key players in the immune defense against infections

and malignancies [23]. Single nucleotide polymorphisms in these receptors lead to different binding affinity of IgG between the receptor allotypes and therefore to varying efficiency in immune defense mechanisms

Table 2 The effect of virus arming on the survival of patients with different FcγR genotype combinations

Genotype	N (all patients)	Treated with GM-CSF virus			Treated with CD40L virus			Treated with GM-CSF and CD40L viruses			Treated with unarmed virus		
		N	P	+ or -	N	P	+ or -	N	P	+ or -	N	P	+ or -
FFHH	24	17	0,783	+/-	4	0,047	+	2	0,034	+	4	0,067	-
FFHR	61	42	0,004	+	9	0,106	+	4	0,222	+	13	<0,0005	-
FFRR	39	27	0,006	+	6	0,175	+/-	2	0,166	+	8	0,016	-
VFHH	30	22	0,194	+	6	0,182	+	5	0,103	+	7	0,283	-
VFHR	39	28	0,093	+	10	0,331	+	4	0,025	+	5	0,179	-
VFRR	22	17	0,061	+	2	NA		0	NA		3	0,122	-
VHH	7	7	NA		0	NA		0	NA		0	NA	
VHR	10	8	0,081	+	0	NA		0	NA		2	0,081	-
VRR	1	1	NA		0	NA		0	NA		0	NA	

P = log rank, + or = benefits or disadvantageous (= better or worse OS estimate) when compared to others.

Kaplan-Meier analyses were performed to study the effect of the virus arming (GM-CSF, CD40L, both or unarmed) on survival of patient with different genotype combinations. Calculations were made by first restricting the study population by each genotype combination and then comparing the overall survival of patient treated with a certain type of virus versus all others. Abbreviations: H histidine allele of FcγRIIa, V valine allele of FcγRIIIa, F phenylalanine allele of FcγRIIIa, CD40L, CD40 ligand, GM-CSF granulocyte macrophage colony-stimulating factor.

between individuals. FcγR polymorphisms have recently been associated with disease severity of multiple immunological diseases [22,23] and responsiveness of immunological cancer therapies [10,11], although there are also reports suggesting lack of association [41]. To date there are also many conflicting results about which genotype predicts the best outcome or survival [16,18,19], however, this might in fact only reflect the fact that different therapies work in different ways so that there will not be a “universal” genotype (marker) that would predict response to all therapies. In this study, we wanted to assess if FcγR polymorphisms have an effect on survival and/or outcome of cancer patients treated with oncolytic adenoviruses and if these polymorphisms could serve as prognostic and/or predictive biomarkers for oncolytic virotherapy to further enable better selection of patients suitable for this novel therapy.

Our analyses included 235 cancer patients that have been treated with oncolytic adenoviruses as an experimental therapy after all other treatment options had failed. We genotyped all patients for two SNPs in FcγR genes, FcγRIIa-H131R and FcγRIIIa-V158F, using TaqMan-based technology. The distribution of FcγRIIa and FcγRIIIa genotypes observed in our study population were relatively similar to those reported previously for Caucasian [18,42-46] and Finnish [47] populations. This confirms the reliability of the genotyping performed in this study. We observed some linkage disequilibrium between the genotypes, which has also been reported in some previous studies in Dutch [42] and Spanish [48] populations.

It is obvious that FcγRs function in concert with each other and with other receptors, especially in the context of a therapy such as oncolytic viruses which are active on several immunological levels. The overall effect of different FcγRs on clinical outcome is currently poorly

understood, but simplistic explanations include proposals that different classes of FcγRs mediate binding by different cell types. For example, it has been proposed that FcγRII is important in the context of antigen presenting macrophages, while FcγRIII is relevant for activity of NK cells [22]. Thus, we were encouraged to investigate the genotype combinations and how they correlate with patient survival and treatment outcome.

In survival estimations one genotype combination (FcγRIIIa-VV + FcγRIIa-HR) stood out as a prognostic factor for poor overall survival after oncolytic virus therapy. Since this genotype did not correlate with length of survival from cancer diagnosis, we hypothesize that this is not a purely prognostic factor but in fact predictive of long survival in patients treated with oncolytic adenoviruses. The small proportion of patients with this genotype combination may limit its clinical utility and therefore our findings may be more interesting from a mechanism-of-action point of view. We also observed another FcγR genotype combination, VFHH (heterozygote for FcγRIIIa and homozygote for FcγRIIa-H allele), to have a trend towards good overall survival, but the correlation was not significant. Interestingly though, this genotype combination was an “opposite” genotype for the poor responder genotype VVHR (homozygote for FcγRIIIa-V allele and heterozygote for FcγRIIa) supporting a possible mechanistic aspect.

We observed that different arming molecules associated differently with survival in patients with different FcγR genotype combinations. This is not very surprising since GM-CSF and CD40L are both potent recruiters and activators of immune cells (e.g. DCs and NK cells) essential for FcγR-mediated effector cell functions. Thus, individuals with FFHR and FFRR genotypes might have lower innate activity of NK cells, and therefore their




Figure 4 (See legend on next page.)

(See figure on previous page.)

Figure 4 The effect of virus arming on the survival of patients with FFHR, FFRR and FFHH genotype combinations. Kaplan-Meier analyses were performed to study the effect of the virus arming (GM-CSF, CD40L or unarmed) on survival of patient with FFHR, FFRR and FFHH genotype combinations. Calculations were made by first restricting the study population by each genotype combination and then comparing the overall survival of patient treated with a certain type of virus versus all others. **a)** Survival of patients with FFHR genotype when threatened with GM-CSF-armed virus vs. others or with unarmed virus vs. others. **b)** Survival of patients with FFRR genotype when threatened with GM-CSF-armed virus vs. others or with unarmed virus vs. others. **c)** Survival of patients with FFHH genotype when threatened with CD40L-armed virus vs. others or with unarmed virus vs. others.

tumors feature less resistance to NK cell mediated killing. When a potent NK recruitment signal is provided by virally produced GM-CSF, anti-tumor efficacy may ensue. Importantly, since the effect of GM-CSF is paracrine, activity of the recruited NK-cells is not only against infected cells, but also against “bystanders”. If the baseline NK activity is low, perhaps infected cells are not cleared as rapidly as when baseline NK activity is high, as predicted for VVHR. These hypotheses are in accord with VVHR correlating with poor survival, as this genotype might indicate high NK responsiveness against infected cells, limiting virus dissemination (Additional file 1: Figure S2).

It has also been shown that many inflammatory molecules, including cytokines and growth factors, can alter FcγR expression and FcγR-mediated immune responses, although not all reports agree. Pleiotropic effects of these inflammatory molecules have been shown to act locally to distract and downregulate FcγR-mediated immune functions [21,26,47,48]. On the other hand, e.g. GM-CSF and IFN-γ have been shown to increase the activity and expression of FcγRIIa and FcγRIIIa (49–52). Possibly these features of GM-CSF and CD40L contributed to long survival in individuals with FFHR and FFRR genotypes (GM-CSF) or FFHH (CD40L); lower baseline activity was compensated by transgene products resulting in immunological activation.

NK cells have been proposed limiting for the efficacy of oncolytic viruses and they are the main cell type expressing FcγRIIIa [49]. NK cells can mediate antibody-dependent cell killing by ADCC, which occurs when the FcγRIIIa molecules on effector cells are cross-linked by binding to the IgG molecules that are present on the target cell [23]. In the case of homozygous individuals for FcγRIIIa-V allotype (VV), infected tumor cells are probably killed efficiently by these “strong binding” receptor variants, possibly before the virus has even had time to replicate effectively. This may result in fierce anti-viral ADCVI (antibody-dependent cell-mediated virus inhibition) [9] against oncolytic adenoviruses partially inhibiting its efficacy.

In line with this thinking, it is logical that intermediate binding of NK cells would be optimal, as ADCVI would not be too prominent, but that infected tumor cells – and bystander cells – would be eventually eradicated. In

other words, the virus has time to replicate and spread while simultaneously the NK cells are still effective enough to kill the tumor cells. This would result in individuals heterozygous for FcγRIIIa polymorphism (VF) benefiting the most. There is always balancing between ADCC and ADCVI that are partly overlapping and competing events in the context of oncolytic virus therapy [9].

FcγRIIIa receptors are widely distributed on many immune cell types, but are mostly considered to be prominent on phagocytic cells, including tissue macrophages, the most important class of antigen presenting cells (APC) [50]. Given the mechanism-of-action of oncolytic adenoviruses armed with immunostimulatory molecules such as GM-CSF, effective recognition of tumor epitopes by APCs seems likely to be important for efficacy and subsequent survival. Therefore, it is logical that we observed the trend for increased survival in HH-homozygotes, which can strongly bind IgG and a significant correlation with survival in CD40L virus treated patients.

Conclusions

According to the results of this study, we suggest that FcγR-mediated blockage of virus infectivity via degradation of immune complexes in APCs and ADCC together with ADCVI could have an effect on oncolytic virotherapy and therefore on the therapy responsiveness. At this point, our understanding of the distribution of the different classes of FcγR on different immunological cells is insufficient to allow drawing of firm conclusions. Moreover, the interplay of different cell types in the context of response to oncolytic virotherapy are poorly understood. Also, due to relatively small and heterogeneous study cohort no definitive conclusions can be drawn from these results and should thus be taken as hypothesis generating rather than conclusive analysis. However, our empiric observation that polymorphisms in FcγRIIa and FcγRIIIa seem to have potential as prognostic and predictive biomarkers for oncolytic adenovirus therapies could eventually enable selection of patients responsive to the treatments. Importantly, this observation was made in real-life human patients treated with oncolytic adenoviruses. The results presented here are, according to our knowledge, the first associations studied between Fcγ receptors and survival of oncolytic virus treated patients. Our data set the stage for prospective study of

these genotypes in the context of trials with oncolytic adenoviruses coding for immunostimulatory molecules. Since many different oncolytic viruses are currently being used, the phenomenon of oncolysis might nevertheless have common features, and the most popular transgenes employed tend to be similar, often featuring immunostimulatory mechanisms of actions. Thus, our data might have relevance for the entire field of cancer therapy with oncolytic viruses. Moreover, as immunological aspects are daunting to study in the laboratory, especially in the context of species-specific agents such as oncolytic adenoviruses, human data could provide important mechanistic data.

Consent

Written informed consent was obtained from the patient for the publication of this report.

Additional file

Additional file 1: Table S1. Observed frequencies of polymorphisms and linkage disequilibrium statistics. **Table S2.** Observed frequencies of genotype combinations. **Table S3.** The effect of virus arming on the survival of patients with different FcγR genotypes. Kaplan-Meier analyses were performed to study the effect of the virus arming (GM-CSF, CD40L, both or unarmed) on survival of patients with different genotypes. Calculations were made by first restricting the study population by each genotype and then comparing the overall survival for patients treated with a certain type of virus versus all other patients. Abbreviations: H, histidine allele of FcγRIIIa; V, valine allele of FcγRIIIa; F, phenylalanine allele of FcγRIIIa; CD40L, CD40 ligand; GM-CSF, granulocyte macrophage colony-stimulating factor. **Figure S1.** FcγRIIIa and FcγRIIIa genotypes are not predictive of imaging results in patients treated with oncolytic adenovirus therapy. Clinical outcome of patients treated with oncolytic adenoviruses by (a) FcγRIIIa-H131R and (b) FcγRIIIa-V158F genotypes. Objective clinical outcome could be determined for 134 patients. Abbreviations: DC, disease control (= stable disease or better); PD, progressive. **Figure S2.** Hypothetical mechanisms-of-action. (a) Strong binding of NK cells to tumor cell-bound IgG (V) causes virus elimination prior to effective oncolytic dissemination. (b) Intermediate activity of NK cells (VF) gives time for the virus to replicate and spread while simultaneously being still effective enough in tumor cell killing. This combined with efficient tumor antigen presentation by APCs (HH) plus the ability of GM-CSF and CD40L to recruit more APCs and other immune cells to the tumor site may explain the good responsiveness to oncolytic adenovirus therapy with armed viruses. Abbreviations: APC, antigen presenting cell; NK cell, natural killer cell; MHC-II, major histocompatibility complex II.

Abbreviations

ADCC: Antibody-dependent cellular cytotoxicity; ADCVI: Antibody-dependent cell-mediated virus inhibition; APC: Antigen presenting cell; CD40L: CD40 ligand; DC: Dendritic cell; FcγR: Fc gamma receptor; GM-CSF: Granulocyte macrophage colony-stimulating factor; ITAM: Immunoreceptor tyrosine-based activation motif; ITIM: Immunoreceptor tyrosine-based inhibition motif; MHC: Major histocompatibility complex; NK: Natural killer cell.

Competing interests

A.H. is shareholder in and consultant to Oncos Therapeutics, Ltd.

Authors' contributions

MH carried out the design of the study, acquisition, analysis and interpretation of the data, statistical analyses and drafted the manuscript. RH and MO helped with patient data analyses. SP helped with DNA extractions

and genotyping. IL wrote the application for Operative Ethics committee and provided advice with patient data. TJ provided the patient material. AK provided scientific advice and help with patient data. VC and AH contributed to conception and design of the study, provided scientific advice and help with manuscript writing. All authors read and approved the final manuscript.

Acknowledgements

We thank Veli-Matti Sorvala for advice in statistical analyses. This work was supported by University of Helsinki, Marie Curie FP7-PEOPLE-IRG-2008, ASCO Foundation, HUCH Research Funds (EVO), Sigrid Juselius Foundation, Academy of Finland, Biocentrum Helsinki, Biocenter Finland and Finnish Cancer Organizations.

Author details

¹Cancer Gene Therapy Group, Department of Pathology and Transplantation laboratory, Haartman Institute, University of Helsinki, Haartmaninkatu 3, Helsinki 00290, Finland. ²Laboratory of Immunovirotherapy, Division of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, Helsinki 00790, Finland. ³Oncos Therapeutics, Ltd., Helsinki, Finland. ⁴Docrates Cancer Center, Helsinki, Finland. ⁵Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland.

Received: 14 June 2013 Accepted: 16 August 2013

Published: 21 August 2013

References

1. Yamamoto M, Curiel DT: **Current issues and future directions of oncolytic adenoviruses.** *Mol Ther* 2010, **18**(2):243–50.
2. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F: **Oncolytic viruses: a novel form of immunotherapy.** *Expert Rev Anticancer Ther* 2008, **8**(10):1581–8.
3. Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A, Nemunaitis J: **Oncolytic viruses for induction, of anti-tumor immunity.** *Curr Pharm Biotechnol* 2011, **13**(9):1750–1760.
4. Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, et al: **Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.** *Mol Ther* 2010, **18**(10):1874–1884.
5. Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, et al: **Immune response is an important aspect of the anti-tumor effect produced by a CD40L-encoding oncolytic adenovirus.** *Cancer Res* 2012, **72**(9):2327–2338.
6. Ravetch JV, Bolland S: **IgG fc receptors.** *Annu Rev Immunol* 2001, **19**:275–90.
7. Dijkstra bloem HM, van de Winkel JG, Kallenberg CG: **Inflammation in autoimmunity: receptors for IgG revisited.** *Trends Immunol* 2001, **22**(9):510–6.
8. Pleass RJ, Woof JM: **Fc receptors and immunity to parasites.** *Trends Parasitol* 2001, **17**(11):545–51.
9. Forthal DN, Moog C: **Fc receptor-mediated antiviral antibodies.** *Curr Opin HIV AIDS* 2009, **4**(5):388–93.
10. Clynes RA, Towers TL, Presta LG, Ravetch JV: **Inhibitory fc receptors modulate in vivo cytotoxicity against tumor targets.** *Nat Med* 2000, **6**(4):443–6.
11. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al: **Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.** *J Clin Oncol* 2008, **26**(11):1789–96.
12. Weng WK, Czerwinski D, Levy R: **Humoral immune response and immunoglobulin G fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy.** *Blood* 2007, **109**(3):951–3.
13. Wang B, Kokhaei P, Mellstedt H, Liljefors M: **FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment.** *Int J Oncol* 2010, **37**(6):1599–606.
14. Weng WK, Levy R: **Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.** *J Clin Oncol* 2003, **21**(21):3940–7.
15. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al: **Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG fc receptor FcγRIIIa gene.** *Blood* 2002, **99**(3):754–8.

16. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al: **Impact of fc(gamma)RIIIa-fc(gamma)RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.** *J Clin Oncol* 2009, **27**(7):1122–9.
17. Rodriguez J, Zarate R, Bandres E, Boni V, Hernandez A, Sola JJ, et al: **Fc gamma receptor polymorphisms as predictive markers of cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.** *Eur J Cancer* 2012.
18. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, et al: **FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.** *J Clin Oncol* 2007, **25**(24):3712–8.
19. Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der Straaten T, et al: **Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.** *Eur J Cancer* 2010, **46**(10):1829–34.
20. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R: **Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G fc receptor genotype.** *J Clin Oncol* 2004, **22**(23):4717–24.
21. Alemany R, Cascallo M: **Oncolytic viruses from the perspective of the immune system.** *Future Microbiol* 2009, **4**(5):527–36.
22. Li X, Ptacek TS, Brown EE, Edberg JC: **Fcgamma receptors: structure, function and role as genetic risk factors in SLE.** *Genes Immun* 2009, **10**(5):380–9.
23. van Sorge NM, van der Pol WL, van de Winkel JG: **FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy.** *Tissue Antigens* 2003, **61**(3):189–202.
24. Cohen-Solal JF, Cassard L, Fournier EM, Loncar SM, Fridman WH, Sautes-Fridman C: **Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity.** *Dermatol Res Pract.* 2010, **2010**:657406.
25. Nimmerjahn F, Ravetch JV: **Fcgamma receptors as regulators of immune responses.** *Nat Rev Immunol* 2008, **8**(1):34–47.
26. Bournazos S, Woof JM, Hart SP, Dransfield I: **Functional and clinical consequences of fc receptor polymorphic and copy number variants.** *Clin Exp Immunol* 2009, **157**(2):244–54.
27. Huang ZY, Chien P, Indik ZK, Schreiber AD: **Human platelet FcgammaRIIA and phagocytes in immune-complex clearance.** *Mol Immunol* 2011, **48**(4):691–6.
28. Miller G, Pillarisetty VG, Shah AB, Lahrs S, Xing Z, DeMatteo RP: **Endogenous granulocyte-macrophage colony-stimulating factor overexpression in vivo results in the long-term recruitment of a distinct dendritic cell population with enhanced immunostimulatory function.** *J Immunol* 2002, **169**(6):2875–85.
29. Iwasaki M, Shimada N, Kasuga Y, Yokoyama S, Onuma H, Nishimura H, et al: **Fragment c gamma receptor gene polymorphisms and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.** *Breast Cancer Res Treat* 2011, **126**(2):497–505.
30. Koski A, Raki M, Nokisalmi P, Liikainen I, Kangasniemi L, Joensuu T, et al: **Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer.** *Mol Ther* 2012, **20**(1):221–9.
31. Liikainen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P, et al: **Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.** *Mol Ther* 2013, **21**(6):1212–1223.
32. Heid CA, Stevens J, Livak KJ, Williams PM: **Real time quantitative PCR.** *Genome Res* 1996, **6**(10):986–94.
33. Rodriguez S, Gaunt TR, Day IN: **Hardy-weinberg equilibrium testing of biological ascertainment for mendelian randomization studies.** *Am J Epidemiol* 2009, **169**(4):505–14.
34. *CubeX* [Internet]; cited 4/15/2012. Available from: <http://www.oege.org/software/cubex/>.
35. Excoffier L, Slatkin M: **Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population.** *Mol Biol Evol* 1995, **12**(5):921–7.
36. Wahl RL, Jacene H, Kasamon Y, Lodge MA: **From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors.** *J Nucl Med* 2009, **50**(Suppl 1):122S–50S.
37. Kaplan EL, Meier P: **Nonparametric estimation from incomplete observations.** *J Am Stat Assoc* 1958:457–81.
38. Mantel N: **Evaluation of survival data and two new rank order statistics arising in its consideration.** *Cancer Chemother Rep* 1966, **50**(3):163–70.
39. Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikainen I, et al: **Anti-viral and anti-tumor T-cell immunity in patients treated with GMCSF coding oncolytic adenovirus.** *Clin Cancer Res* 2013, **19**(10):2734–2744.
40. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, et al: **Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.** *Cancer Res* 2010, **70**(11):4297–309.
41. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, et al: **Analysis of fcgamma receptor IIIa and IIIb polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.** *Clin Cancer Res* 2012, **18**(12):3478–86.
42. van der Pol WL, Jansen MD, Sluiter WJ, van de Sluis B, de Straat FG L-v, Kobayashi T, et al: **Evidence for non-random distribution of fcgamma receptor genotype combinations.** *Immunogenetics* 2003, **55**(4):240–6.
43. de Straat FG L-v, van der Pol WL, Jansen MD, Sugita N, Yoshie H, Kobayashi T, et al: **A novel PCR-based method for direct fc gamma receptor IIIa (CD16) allotyping.** *J Immunol Methods* 2000, **242**(1–2):127–32.
44. Van Den Berg L, Myhr KM, Kluge B, Vedeler CA: **Fcgamma receptor polymorphisms in populations in Ethiopia and Norway.** *Immunology* 2001, **104**(1):87–91.
45. *rs1801274 TaqMan SNP genotyping assays* [Internet]; cited 4/15/2012. Available from: https://bioinfo.appliedbiosystems.com/genome-database/searchResults?offset=0&searchMode=keyword&CID=&productTypeSelect=genotyping&alternateTargetTypeSelect=&targetTypeSelect=snp_all&species=Homo+sapiens&otherSpecies=&keyword=rs1801274&sequenceInput=&chromosome=&chromStart=&chromStop=&btnSearch=y&batchText=&batchUpload=.
46. *rs396991 TaqMan SNP genotyping assays* [Internet]; cited 4/15/2012. Available from: https://bioinfo.appliedbiosystems.com/genome-database/searchResults?offset=0&searchMode=keyword&CID=&productTypeSelect=genotyping&alternateTargetTypeSelect=&targetTypeSelect=snp_all&species=Homo+sapiens&otherSpecies=&keyword=rs396991&sequenceInput=&chromosome=&chromStart=&chromStop=&btnSearch=y&batchText=&batchUpload=.
47. Sarvas H, Vesterinen P, Makela O: **Serum IgG2 concentration is associated with gm-allotypes of IgG2 but not with the R131H polymorphism of human fc-gamma receptor type IIa.** *J Clin Immunol* 2002, **22**(2):92–7.
48. Morgan AW, Robinson JI, Barrett JH, Martin J, Walker A, Babbage SJ, et al: **Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis.** *Arthritis Res Ther* 2006, **8**(4):R109.
49. Alvarez-Breckenridge CA, Yu J, Kaur B, Caligiuri MA, Chiozza EA: **Deciphering the multifaceted relationship between oncolytic viruses and natural killer cells.** *Adv Virol.* 2012, **2012**:702839.
50. Jefferis R, Lund J: **Interaction sites on human IgG-fc for FcgammaR: current models.** *Immunol Lett* 2002, **82**(1–2):57–65.

doi:10.1186/1479-5876-11-193

Cite this article as: Hirvinen et al.: Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. *Journal of Translational Medicine* 2013 **11**:193.

Submit your next manuscript to BioMed Central and take full advantage of:

- **Convenient online submission**
- **Thorough peer review**
- **No space constraints or color figure charges**
- **Immediate publication on acceptance**
- **Inclusion in PubMed, CAS, Scopus and Google Scholar**
- **Research which is freely available for redistribution**

Submit your manuscript at
www.biomedcentral.com/submit

